Aclarion, Inc.

ACON · NASDAQ

Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.

Follow Add to Watchlist Ask Question

NASDAQ ACON Coverage Bootstrap Healthcare Technology Diagnostics Medical Software

Latest ReportMay 13, 2026Aclarion: the $19M cash pile chasing a tiny Nociscan revenue lineView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

NasdaqACON

Clear tags

MatchAny tag All tags

Latest Thesis

Aclarion: the $19M cash pile chasing a tiny Nociscan revenue line

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Aclarion, Inc.the $19M cash pile chasing a tiny Nociscan revenue lineMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Aclarion: the $19M cash pile chasing a tiny Nociscan revenue lineAclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reimbursed repeat volume.NASDAQMay 13, 2026Research reportRead Slides